Monopar Therapeutics — Director's Dealing 2025

Jul 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-07-14

Reporting Person: STARR CHRISTOPHER M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-14	Common Stock	X	16800	$0.005	Acquired	21973	Direct
2025-07-14	Common Stock	S	16800	$40.0012	Disposed	5173	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-14	Stock Options	$0.005	X	16800	Disposed	2026-04-04	Common Stock (16800)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9880	Indirect

Footnotes

F1: This transaction involved a cash exercise of stock options.

F2: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3: 9,880 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee

F4: Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.